Solventum (NYSE:SOLV) Price Target Raised to $82.00

Solventum (NYSE:SOLV) had its price objective boosted by Wells Fargo & Company from $79.00 to $82.00 in a research note released on Monday,Benzinga reports. The brokerage currently has an equal weight rating on the stock.

SOLV has been the topic of a number of other research reports. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a research note on Tuesday, July 1st. KeyCorp began coverage on Solventum in a research note on Friday, June 6th. They issued a “sector weight” rating for the company. Wall Street Zen cut Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. Finally, Jefferies Financial Group initiated coverage on shares of Solventum in a report on Thursday, September 11th. They set a “hold” rating and a $80.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $85.44.

Solventum Price Performance

SOLV opened at $74.10 on Monday. Solventum has a 1 year low of $60.70 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The company has a market capitalization of $12.85 billion, a price-to-earnings ratio of 34.31, a P/E/G ratio of 3.02 and a beta of 0.53. The firm’s fifty day moving average price is $73.01 and its two-hundred day moving average price is $72.48.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same period last year, the firm earned $1.56 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, analysts anticipate that Solventum will post 6.58 earnings per share for the current fiscal year.

Institutional Trading of Solventum

A number of institutional investors have recently made changes to their positions in the stock. Rossby Financial LCC bought a new position in shares of Solventum in the first quarter worth approximately $25,000. Strengthening Families & Communities LLC raised its holdings in Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the last quarter. CYBER HORNET ETFs LLC purchased a new stake in Solventum during the 2nd quarter valued at $28,000. Raiffeisen Bank International AG bought a new stake in Solventum in the 4th quarter worth $29,000. Finally, Barrett & Company Inc. increased its position in shares of Solventum by 206.2% in the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.